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Primary central nervous system lymphoma (PCNSL), a rare form of extranodal non-
Hodgkin’s lymphoma (NHL), occurs in the brain, leptomeninges, spinal cord, or eyes, and
typically remains confined to the CNS.
1
The prognosis of immunocompetent patients diagnosed with PCNSL has improved
during the last decade with the introduction of methotrexate-based regimens and cranial
radiotherapy.
2,3 However, failure after first-line therapy has been reported in 35-60% of
patients with PCNSL.
2,4 Patients who are refractory to primary therapy or relapse after an
initial response have a poor prognosis, with median survival of 2 months without further
treatment. The information on salvage therapies is limited and, in most published series of
patients with PCNSL treated initially with a uniform regimen, the therapies given for
relapse have been heterogeneous.
4,5
Here, we report a relapsed PCNSL patient who was successfully treated with intraven-
tricular applications of rituximab to minimize neurotoxicity, 2 cycles of chemotherapy
with etoposide, ifosfamide, and cytarabine (VIA) regimen and high-dose chemotherapy
with autologous stem cell rescue.
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INTRODUCTION
Case Report
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headache and dizziness that had continued for 2 weeks. The
patient’s physical examination demonstrated no focal neurolo-
gical abnormalities. The Eastern Cooperative Oncology Group
(ECOG) performance status was 1 and she had no B symptoms.
6
MRI-contrast enhanced images showed 4 cm sized homoge-
neously and highly enhanced masses at left basal ganglia with
right-sided subfalcine herniation. The stereotactic brain biopsy
was performed on April 10, 2003. Histopathology confirmed
diffuse large B-cell lymphoma. There was no evidence of
systemic lymphadenopathy or ocular involvement and no
evidence of bone marrow or cerebrospinal fluid (CSF) involve-
ment. CSF protein concentration was within normal ranges.
The biochemical profile revealed lactic dehydrogenate (LDH)
levels of 322 IU/L (normal range, 101-202 IU/L) and β2-
microglobulin level of 0.5  mg/dL (normal range, 0-2.7 mg/dL).
The results of serologic tests for HIV, hepatitis B and C virus,
and Ebstein-Barr virus were negative.
The patient received chemotherapy with CHOD/BVAM
regimen [CHOD = cyclophosphamide (750 mg/m
2 on day 1),
doxorubicin (50 mg/m
2 on day 1), vincristine (1.4 mg/m
2 on
day 1), dexamethasone (4 mg orally on days 1 through 7);
BVAM (= 2×42-day cycles) = carmustine (100 mg/m
2 on days
8 and 50), vincristine (1.4 mg/m
2 On days 15, 29, 43, 57, 71,
85), methotrexate (1.5 g/m
2 on days 15, 29, 43, 57, 71, 85),
cytarabine (3 g/m
2 on days 16, 30, 44, 58, 72, 86)] and achieved
partial remission. After chemotherapy, the patient was treated
with radiotherapy, 45 Gy whole-brain irradiation in 25 fractions
during a 5-week period, plus a boost 10 Gy in five fractions in
1-week, and she achieved complete remission (CR).
She visited the emergency room in July 2006 with left-right
postural sway and transient aphasia. The PCNSL relapsed and
the first CR was maintained for 34 months. Brain MRI and a
staging workup revealed newly appearing lesions in the right
thalamus and splenium of the corpus callosum without any
identifiable systemic tumor mass or bone marrow involvement
(Fig. 1). The patient received the 1st salvage chemotherapy.
Rituximab alone without concomitant systemic steroid or other
chemotherapeutic drugs was administered at a dose of 20 mg
twice a week for 2 weeks via Ommaya reservoir whose tip was
located in the left lateral ventricle. A partial remission of the
parenchymal tumor was detectable after 2 weeks of intraven-
tricular rituximab applications, total dose of 80 mg (Fig. 2). The
patient was treated with 2 courses of the VIA (etoposide,
ifosfamide, cytarabine) chemotherapy, and peripheral blood
stem cells were harvested at the end of the 1st cycle of VIA
chemotherapy. VIA included etoposide 100 mg/m
2 on days 1
through 3, ifosfamide 1 g/m
2 on days 1 through 5, and cytarabine
2 g/m
2/12 h on day 1.
The patient received high-dose chemotherapy with a BEAM
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Fig. 3. Full regression of lymphoma infiltration after 2 cycles of VIA chemotherapy and
high-dose chemotherapy with autologous stem-cell rescue.
Fig. 2. About 50% reduction of the lesion size in the right thalamus after treatment of
intraventricular rituximab.
Fig. 1. Gadolinium-enhanced, T1-weighted, MRI shows an enhancing lesion involving
the right thalamus and splenium of the corpus callosum at relapse.regimen (bischloroethylnitrosourea 300 mg/m
2 on day -7,
etoposide 200 mg/m
2 on days -6 through -3, cytarabine 200
mg/m
2 on days -6 through -3, and melphalan 140 mg/m
2 on day
-2), and autologous peripheral blood stem cells (6.04×10
6
CD34
+ cells/kg on day 0 and 6.93×10
6 CD34
+ cells/kg on day
1) were infused on November 2006. The treatment was well-
tolerated, and a MRI scan performed by the end of January 2007
showed full regression of lymphoma infiltration (Fig. 3). The
patient has been in remission for 28 months after high-dose
chemotherapy with autologous stem cell rescue.
The prognosis for patients with PCNSL refractory to initial
treatment or those who relapse after initial response is usually
poor. Without treatment, median survival is usually less than 3
months.
5 The most appropriate therapeutic approach of refrac-
tory or relapsed PCNSL has not yet been established because of
the heterogeneity of the therapies employed and the lack of
large, prospective clinical trials. However, second-line treat-
ment for PCNSL is probably beneficial for those patients. A
retrospective analysis of salvage treatment in 173 patients cited
in 24 papers reports the results of upfront treatment for PCNSL
and showed that the median survival after relapse or progression
was 14 months in the group of patients who receive second-line
treatment compared with only 2 months for those who were
treated by only supportive therapy.
5
We treated the patient with relapsed PCNSL with intraven-
tricular rituximab as initial salvage regimen to minimize
neurotoxicity. Neurotoxicity is a potentially devastating com-
plication that can occur in response to antineoplastic therapies.
This complication can manifest in a variety of ways, including
impaired cognition, ataxia, and incontinence, and is associated
with a significant decline in the quality of life. Among the
different therapeutic strategies for PCNSL, whole-brain
radiotherapy followed by methotrexate-based chemotherapy
seems to produce the highest incidence of neurotoxicity,
followed by whole-brain radiotherapy alone, and then chemo-
therapy alone.
1 This patient may be a high-risk patient who will
easily develop neurotoxicity if she received repeated salvage
chemotherapy because she received high-dose methotrexate-
based combination chemotherapy and whole-brain radiotherapy
(total 55 Gy) as the initial treatment. Therefore, intraventricular
rituximab therapy instead of repeated salvage chemotherapy as
an initial salvage regimen may maximize response rate and
minimize neurotoxicity.
Rituximab is a chimeric monoclonal antibody against the B-
cell specific CD20-antigen that has proven to be highly effec-
tive in the treatment of B-cell NHL. When administered
intravenously, rituximab concentrations in the CSF are very
low and they are not increased significantly upon repeated
intravenous administration. The high molecular weight of
rituximab (146 kDa) might limit its uptake into brain parenc-
hyma after systemic application.
7 Because of that reason, there
are several case reports of the relapsed PCNSL treated with
intrathecal rituximab application. Although the clinical exper-
ience reported so far is very limited.
8-11 the safety of intrathecal
rituximab is in accordance with experimental studies, which
showed that there was no clinical evidence of neurotoxicity
after seven intrathecal administrations in cynomolgus mon-
keys.
12 Recently, phase I study investigating intraventricular
dose intensification, toxicity, and pharmacokinetics of rituxi-
mab in patients with PCNSL was performed, and the result
suggested that intrathecal rituximab at the doses from 10 to 25
mg is feasible and effective. Intrathecal rituximab at 50 mg was
associated with grade 3 infusion-related hypertension, nausea,
vomiting, and abdominal cramping.
13 The estimated elimination
half-life averaged 34.9 hours on multiple dosing twice weekly
at 25 mg, and serum concentrations rose steadily and were still
increasing at the time of the last intraventricular dose, but were
still far below CSF concentrations.
13 Therefore, intraventricular
rituximab at a dose of 20 mg twice a week in this case might be
a safe and effective schedule in the treatment of relapsed
PCNSL patients.
Intraventricular rituximab alone seems to be not sufficient to
achieve and maintain CR for a long time. Schulz et al.
9 reported
a series of six patients in whom rituximab was used as intra-
thecal or intraventricular and systemically. CSF tumor cells
were almost completely cleared in most of the patients,
however, parenchymal disease did not respond.
9 Rubenstein et
al.
13 also reported poor response in parenchymal lesions in phase
I study. According to Akyuz et al.,
11 there was only one case of
PCNSL responding completely after systemic and intraventri-
cular rituximab application. In our patient, the size of the
relapsed tumor was reduced by about 50% after intraventricular
rituximab application, but could not achieve CR as we expected.
She needed additional therapy, nevertheless she received only 2
cycles of chemotherapy with VIA regimen before high-dose
chemotherapy with autologous stem cell rescue. Although it is
difficult to expect CR with intraventricular rituximab applica-
tion alone in relapsed PCNSL, it should be considered for
salvage treatment to minimize neurotoxicity before additional
therapy such as systemic chemotherapy or high-dose chemo-
therapy with autologous stem cell rescue.
Arellano-Rodrigo et al.
14 reported the results in terms of
response and survival to the VIA regimen as a salvage treatment
for 16 relapsed PCNSL patients after the CHOD/BVAM
regimen and radiotherapy. Six patients (37%) achieved CR.
After median follow-up of 15 months for surviving patients,
two have relapsed with a median failure-free survival of 5
months. Twelve patients have died from progression of PCNSL
with a 12-month overall survival of 41%.
14
High-dose chemotherapy followed by hematopoietic stem
cell rescue is now the standard treatment for patients with
relapses of chemo-sensitive, aggressive, systemic NHL without
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DISCUSSIONCNS involvement.
15 The importance of high-dose chemotherapy
with autologous stem cell rescue also should be emphasized in
the patients with relapsed and chemo-sensitive PCNSL.
Soussain et al.
16 reported 80% CR rate and a 3-years probability
of 63.7% survival in relapsed PCNSL patients who were
treated with high-dose chemotherapy together with autologous
stem cell rescue. Our patient also achieved CR after this proce-
dure, and the present case report suggests that high-dose
chemotherapy and autologous stem cell rescue are feasible and
effective in patients with recurrent PCNSL. 
Although the standard salvage treatment for relapsed PCNSL
has not yet been established, intraventricular rituximab appli-
cation followed by short courses of systemic chemotherapy and
high-dose chemotherapy with autologous stem cell rescue is a
feasible and effective treatment plan in patients with relapsed
PCNSL. Intraventricular rituximab application should be consi-
dered for salvage treatment to minimize neurotoxicity.
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